BioCentury
ARTICLE | Clinical News

Cel-Sci to begin Phase II

June 28, 2000 7:00 AM UTC

Cel-Sci (CVM; Berlin:LSR) will begin a Phase II trial in Canada of its Multikine immunotherapy adjuvant to treat head and neck cancer. The study will enroll up to 20 patients in two dose groups. Multi...